Agendia nets $65 million for cancer tests
IRVINE, Calif.óAgendia, which specializes in cancer diagnostics and personalized medicine, recently announced the successful close of a private round of equity financing that netted the company $65 million. Debiopharm Group led the financing round, with support from Agendia's existing investors as well, including ING Corporate Investments, Gilde Healthcare, the Van Herk Group and Breedinvest. Other new investors also participated, including Korys, the investment structure of the Colruyt family, and others.
"We will use these funds to expand commercialization of our current breast cancer Symphony suite of tests, as well as for development of our personalized medicine pipeline. We have recently launched our Symphony suite in an FFPE format, and we are preparing to launch our ColoPrint recurrence test for stage II colon cancer prognosis and prediction," David Macdonald, Agendia's CEO, said in a statement.